The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause

Publikation

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause

Wissenschaftlicher Artikel/Review - 04.09.2011

Chirgwin Jacquie, Coates Alan S, Goldhirsch Aron, Regan Meredith M, Bonnefoi Hervé, Ejlertsen Bent, Thürlimann Beat, Price Karen N, Smith Ian, Sun Zhuoxin, BIG 1-98 Collaborative and International Breast Cancer Study Groups

Chirgwin, Jacquie

Sun, Zhuoxin

Smith, Ian

Price, Karen N

Thürlimann, Beat

259

The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause

Chirgwin, Jacquie

Sun, Zhuoxin

Smith, Ian

Price, Karen N

Thürlimann, Beat

Ejlertsen, Bent

Bonnefoi, Hervé

Regan, Meredith M

Goldhirsch, Aron

Coates, Alan S

BIG 1-98 Collaborative and International Breast Cancer Study Groups,